Cantor Fitzgerald Reiterates Overweight on Monopar Therapeutics, Maintains $74 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and maintains $74 price target.
Cantor Fitzgerald analyst Kristen Kluska reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and maintains $74 price target.